Keywords: Astellas, Darexaban, Anticoagulant, Development dropped
Astellas drops development of blood thinner darexaban
Article | 29 September 2011
Japanese drug major Astellas Pharma (TYO: 4503) says it has decided to discontinue the global development of darexaban maleate (development code ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Italy's pharma market slump set to continue, warns GlobalData
